ファーマコビジランス市場規模、シェア、成長分析：ライフサイクル別、タイプ別、展開別、エンドユーザー別、地域別 - 産業予測 2025～2032年

ファーマコビジランス市場規模は2023年に75億米ドルと評価され、2024年の80億1,000万米ドルから2032年には135億6,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは6.8％で成長する見通しです。

世界のファーマコビジランス市場は、患者の安全性重視の高まり、規制当局の厳しい要求、製薬部門の拡大に後押しされ、力強い成長を遂げています。主な促進要因としては、新しい治療法の開発が複雑化し、医薬品消費量が増加する中で、医薬品安全性監視の必要性が高まっていることが挙げられます。規制当局がより厳格なガイドラインを施行する中、製薬会社はファーマコビジランス業務の強化を余儀なくされ、市場の拡大をさらに刺激しています。さらに、慢性疾患の急増は、医薬品副作用の特定と緩和におけるファーマコビジランスの重要な役割を浮き彫りにし、それによって患者の安全性を高め、ヘルスケアコストを削減します。ヘルスケア提供者と規制機関が効果的なファーマコビジランスシステムを優先させる努力を組み合わせることで、医療成果と患者の福祉を大幅に改善することを目指しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ
• 技術の進歩
• 貿易分析

ファーマコビジランス市場規模：ライフサイクル別& CAGR（2025-2032）

• 市場概要
• 前臨床
• フェーズI
• フェーズII
• フェーズIII
• フェーズIV

ファーマコビジランス市場規模：タイプ別& CAGR（2025-2032）

• 市場概要
• 自発的な報告
• ADR報告の強化
• 対象を絞った自発的な報告
• コホートイベントモニタリング
• EHRマイニング

ファーマコビジランス市場規模：展開別& CAGR（2025-2032）

• 市場概要
• 社内
• 契約アウトソーシング

ファーマコビジランス市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 契約調査機関（CRO）
• 製薬・バイオテクノロジー企業
• その他

ファーマコビジランス市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Accenture（Ireland）
• IQVIA Inc.（United States）
• Cognizant（United States）
• IBM Corporation（United States）
• Capgemini（France）
• ITClinical（Portugal）
• ICON plc（Ireland）
• TAKE Solutions Limited（India）
• Parexel International Corporation（United States）
• Wipro（India）
• United BioSource LLC（United States）
• BioClinica Inc.（Clario）（United States）
• ClinChoice（formerly FMD K&L）（United States）
• Linical Americas（United States）
• Science 37 Holdings, Inc.（United States）
• LEO Pharma（Denmark）
• argenx（Belgium）
• Purisys（United States）

結論と提言

PharmaCovigilances Market size was valued at USD 7.5 billion in 2023 and is poised to grow from USD 8.01 billion in 2024 to USD 13.56 billion by 2032, growing at a CAGR of 6.8% during the forecast period (2025-2032).

The global pharmacovigilance market is witnessing robust growth, propelled by an increasing emphasis on patient safety, stringent regulatory demands, and the expanding pharmaceutical sector. Key drivers include the heightened necessity for drug safety monitoring amid the complexity of new therapeutic developments and rising drug consumption. As regulatory agencies enforce more rigorous guidelines, pharmaceutical companies are compelled to enhance their pharmacovigilance practices, further stimulating market expansion. Additionally, the surge in chronic disease prevalence underscores the critical role of pharmacovigilance in identifying and mitigating adverse drug reactions, thereby enhancing patient safety and reducing healthcare costs. The combined efforts of healthcare providers and regulatory bodies to prioritize effective pharmacovigilance systems aim to improve healthcare outcomes and patient welfare significantly.

Top-down and bottom-up approaches were used to estimate and validate the size of the Pharmacovigilances market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Pharmacovigilances Market Segments Analysis

Global PharmaCovigilances Market is segmented by Life Cycle, Type, Deployment, End User and region. Based on Life Cycle, the market is segmented into Pre-clinical, Phase I, Phase II, Phase III and Phase IV. Based on Type, the market is segmented into Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining. Based on Deployment, the market is segmented into In-house and Contract Outsourcing. Based on End User, the market is segmented into Contract Research Organizations (CROs), Pharmaceutical & Biotechnology Companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Pharmacovigilances Market

The global pharmacovigilance market is experiencing significant growth due to the rising prevalence of adverse drug reactions (ADRs) worldwide. As pharmaceutical product usage continues to grow, so does the likelihood of individuals facing unexpected side effects. Pharmacovigilance is essential for monitoring and reporting these ADRs, enabling early detection, risk assessment, and the implementation of necessary actions to protect patient health. The increasing need for effective pharmacovigilance services and solutions is driven by the urgency to manage the escalating rates of ADRs, thereby contributing to the market's expansion and highlighting its vital importance in ensuring drug safety.

Restraints in the Pharmacovigilances Market

A notable challenge within the global pharmacovigilance market is the limited awareness and insufficient infrastructure present in developing regions. These areas struggle to create and implement comprehensive pharmacovigilance systems. The lack of understanding about the importance of pharmacovigilance, coupled with weak regulatory frameworks and resource limitations, hampers the integration of effective practices. Additionally, the presence of inadequate infrastructure, a shortage of trained personnel, and poor data management systems contribute to obstacles for the advancement of the pharmacovigilance market in these regions, ultimately impeding its growth and effectiveness in ensuring drug safety.

Market Trends of the Pharmacovigilances Market

The pharmacovigilance market is witnessing robust growth driven by the escalating consumption and development of pharmaceuticals, significantly increasing the necessity for monitoring drug safety. With high-profile recalls like Aurobindo Pharma's 2022 Quinapril withdrawal, the industry is under pressure to manage adverse drug reactions effectively. This has led regulatory authorities to demand more extensive medical information, fueling market expansion. Additionally, partnerships such as IQVIA's collaboration with NRx Pharmaceuticals signal a strategic shift towards comprehensive pharmacovigilance services, enhancing compliance and patient safety. As awareness of drug-related risks rises, the pharmacovigilance sector is poised for sustained growth, underscoring its critical role in healthcare.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement
• Trade Analysis

Global PharmaCovigilances Market Size by Life Cycle & CAGR (2025-2032)

• Market Overview
• Pre-clinical
• Phase I
• Phase II
• Phase III
• Phase IV

Global PharmaCovigilances Market Size by Type & CAGR (2025-2032)

• Market Overview
• Spontaneous Reporting
• Intensified ADR Reporting
• Targeted Spontaneous Reporting
• Cohort Event Monitoring
• EHR Mining

Global PharmaCovigilances Market Size by Deployment & CAGR (2025-2032)

• Market Overview
• In-house
• Contract Outsourcing

Global PharmaCovigilances Market Size by End User & CAGR (2025-2032)

• Market Overview
• Contract Research Organizations (CROs)
• Pharmaceutical & Biotechnology Companies
• Others

Global PharmaCovigilances Market Size & CAGR (2025-2032)

• North America (Life Cycle, Type, Deployment, End User)
  • US
  • Canada
• Europe (Life Cycle, Type, Deployment, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Life Cycle, Type, Deployment, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Life Cycle, Type, Deployment, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Life Cycle, Type, Deployment, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Accenture (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IQVIA Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cognizant (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IBM Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Capgemini (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ITClinical (Portugal)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICON plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TAKE Solutions Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Parexel International Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wipro (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• United BioSource LLC (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioClinica Inc. (Clario) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ClinChoice (formerly FMD K&L) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Linical Americas (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Science 37 Holdings, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LEO Pharma (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• argenx (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Purisys (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations